Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer

Oncogene volume 22, pages 734–739 (2003)Cite this article

Abstract

Cdc25B is a dual-specific phosphatase that mediates cell cycle progression by activating the cyclin-dependent kinases. It has been shown to possess oncogenic potential. To elucidate its potential contribution to human prostate cancer development, the expression profile of Cdc25B protein in human patients was analysed by immunohistocytochemistry. Cdc25B is frequently overexpressed in human prostate cancer tissues (29 of 30; 97%). In addition, the overexpression is more profound in the tumors of high combined Gleason scores and in late stages. Subsequently, we demonstrated that Cdc25B acts as a coactivator for AR in a hormone-dependent manner in the prostate cancer cell line, LNCaP. This coactivator function, surprisingly, is independent of its cell cycle functions. Cdc25B, on the other hand, directly interacts with AR as evidenced in GST-pull down and mammalian two-hybrid assays. In addition, it is also able to enhance AR-mediated transcription in synergy with other coactivators, including CREB-binding protein (CBP) and p300/CBP associated factor. Therefore, upregulation of Cdc25B in human prostate cancer and its interplay with AR may contribute to prostate cancer development.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Catalona WJ . (1994). N Engl J Med, 331, 996–1004.

  • Draetta G and Eckstein J . (1997). Biochim Biophys Acta, 1332, M53–M63.

  • Galaktionov K and Beach D . (1991). Cell, 67, 1181–1194.

  • Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M and Beach D . (1995). Science, 269, 1575–1577.

  • Gasparotto D, Maestro R, Piccinin S, Vukosavljevic T, Barzan L, Sulfaro S and Boiocchi M, (1997). Cancer Res, 57, 2366–2368.

  • Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE and Robson CN . (2001). Br J Cancer, 85, 1928–1936.

  • Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS and Wilson EM . (2001). Cancer Res, 61, 4315–4319.

  • Hernandez S, Hernandez L, Bea S, Cazorla M, Fernandez PL, Nadal A, Muntane J, Mallofre C, Montserrat E, Cardesa A and Campo E . (1998). Cancer Res, 58, 1762–1767.

  • Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW and Barrett JC . (1999). Cancer Res, 59, 5724–5731.

  • Ma ZQ, Chua SS, DeMayo FJ and Tsai SY . (1999a). Oncogene, 18, 4564–4576.

  • Ma ZQ, Tsai MJ and Tsai SY . (1999b). J Steroid Biochem Mol Biol, 69, 155–163.

  • Ma ZQ, Zheng L, Ngan ESW and Tsai SY . (2001). Mol Cell Biol, 21, 8056–8067.

  • McInerney EM, Tsai MJ, O'Malley BW and Katzenellenbogen BS . (1996). Proc Natl Acad Sci USA, 93, 10069–10073.

  • Nagata A, Igarashi M, Jinno S, Suto K and Okayama H . (1991). New Biol, 3, 959–968.

  • Parker SL, Tong T, Bolden S and Wingo PA . (1997). CA Cancer J Clin, 47, 5–27.

  • Xu X and Burke SP . (1996). J Biol Chem, 271, 5118–5124.

  • Zhang ZY, Wang Y and Dixon JE . (1994). Proc Natl Acad Sci USA, 91, 1624–1627.

Download references

Acknowledgements

We thank F Petit and C Zhou for their critical review of this manuscript. This work was supported by the NIH and the DAMD grants to SY Tsai and NCI prostate spore grant to M-J Tsai. ESW Ngan is a recipient of the postdoctoral fellowship from the Croucher Foundation, Hong Kong, SAR, China and ZQ Ma is a recipient of fellowship from Department of Defense (DAMD-17-98-1-8025).

Author information

Authors and Affiliations

  1. Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, 77030, TX, USA

    Elly S W Ngan, Yoshihiro Hashimoto, Zhi-Qing Ma, Ming-Jer Tsai & Sophia Y Tsai

Authors
  1. Elly S W Ngan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhi-Qing Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ming-Jer Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sophia Y Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sophia Y Tsai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ngan, E., Hashimoto, Y., Ma, ZQ. et al. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 22, 734–739 (2003). https://doi.org/10.1038/sj.onc.1206121

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206121

Keywords

This article is cited by

Search

Advanced search

Quick links